PIKK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia

被引:177
作者
Hayes, Monica Prasad
Wang, Hong
Espinal-Witter, Rosanny
Douglas, Wayne
Solomon, Garron J.
Baker, Suzanne J.
Ellenson, Lora Hedrick
机构
[1] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA
[2] Mt Sinai Sch Med, Div Gynecol Oncol, New York, NY USA
[3] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA
关键词
D O I
10.1158/1078-0432.CCR-06-1375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The tumor suppressor PTEN gene and the PIK3CA oncogene are frequently mutated in uterine endometrioid carcinoma (UEC). PTEN mutations are also common in complex atypical hyperplasia (CAH), the precursor lesion of UEC. The status of PIK3CA has not yet been explored in CAH. In this study, we evaluated both CAH and UEC for PTEN and PIK3CA mutations. Experimental Design: Neoplastic tissue was microdissected, and DNA was extracted from 29 cases of CAH. DNA was available from 44 UEC cases previously characterized for PTEN mutations. Direct DNA sequencing of exons 9 and 20 of the PIK3CA gene was done on all 73 cases. In addition, CAH cases were analyzed for PTEN mutations. Statistical analyses were done using the Fisher's exact test. Results: Two (7%) of 29 CAH and 17 (39%) of 44 UEC cases contained a PIK3CA mutation (P = 0.003). Fourteen (48%) of 29 CAH cases had a PTEN mutation, but none contained both a PTEN and PIK3CA mutation. Twenty-five (57%) of 44 UEC cases had a PTEN mutation, and 12 (48%) of these 25 cases also contained a PIK3CA mutation. Coexistent PIK3CA and PTEN mutations were significantly correlated with UEC compared with CAH (P = 0.002), but the association in UEC did not reach statistical significance (P = 0.21). Conclusions: PIK3CA is the most commonly mutated oncogene in UEC; however, mutations are uncommon in CAH. Thus, mutations in PIK3CA, unlike PTEN mutations, are associated with invasion. These findings suggest that mutations in PIK3CA may serve as a marker of invasion with potential clinical use. Furthermore, PIK3CA and PTEN mutations may play distinct roles in endometrial tumorigenesis.
引用
收藏
页码:5932 / 5935
页数:4
相关论文
共 25 条
[1]   Cancer-specific mutations in PIK3CA are oncogenic in vivo [J].
Bader, AG ;
Kang, SY ;
Vogt, PK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) :1475-1479
[2]   Mutation of the PIK3CA gene in ovarian and breast cancer [J].
Campbell, IG ;
Russell, SE ;
Choong, DYH ;
Montgomery, KG ;
Ciavarella, ML ;
Hooi, CSF ;
Cristiano, BE ;
Pearson, RB ;
Phillips, WA .
CANCER RESEARCH, 2004, 64 (21) :7678-7681
[3]   The phosphoinositide 3-kinase pathway [J].
Cantley, LC .
SCIENCE, 2002, 296 (5573) :1655-1657
[4]  
ENOMOTO T, 1991, CANCER RES, V51, P5308
[5]   Functional analysis of PIK3CA gene mutations in human colorectal cancer [J].
Ikenoue, T ;
Kanai, F ;
Hikiba, Y ;
Obata, T ;
Tanaka, Y ;
Imamura, J ;
Ohta, M ;
Jazag, A ;
Guleng, B ;
Tateishi, K ;
Asaoka, Y ;
Matsumura, M ;
Kawabe, T ;
Omata, M .
CANCER RESEARCH, 2005, 65 (11) :4562-4567
[6]   Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells [J].
Isakoff, SJ ;
Engelman, JA ;
Irie, HY ;
Luo, J ;
Brachmann, SM ;
Pearline, RV ;
Cantley, LC ;
Brugge, JS .
CANCER RESEARCH, 2005, 65 (23) :10992-11000
[7]   Cancer statistics, 2006 [J].
Jemal, A ;
Siegel, R ;
Ward, E ;
Murray, T ;
Xu, JQ ;
Smigal, C ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (02) :106-130
[8]   Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic [J].
Kang, SY ;
Bader, AG ;
Vogt, PK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) :802-807
[9]   Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma [J].
Kendall, BS ;
Ronnett, BM ;
Isacson, C ;
Cho, KR ;
Hedrick, L ;
Diener-West, M ;
Kurman, RJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (08) :1012-1019
[10]  
KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO